Hydrocodone: Rescheduled, Repositioned & Reinvented

The Impact of Hydrocodone Rescheduling,
Zohydro™ ER, and Abuse-deterrent Formulations

Pain Insights, Inc. announces a comprehensive market research study conducted among primary care physicians and other key specialties prescribing hydrocodone combination products. The report reveals how the scheduling change from Schedule III to II, which imposes more stringent regulations on prescribers, could impact the pain market. The survey also assesses the effect of new medications, including the concept of an abuse-deterrent, extended-release hydrocodone on unmet market needs.

Hydrocodone is the most frequently prescribed opioid in the United States with over 129 million prescriptions for hydrocodone-acetaminophen products dispensed in 2013 (IMSHealth™). It will be important to understand practitioner views on the rescheduling of hydrocodone combination products and any impact on prescribing dynamics.

Study content:

The principals at Pain Insights, Inc. have researched issues pertinent to hydrocodone and the management of pain for more than 25 years. We are pleased to make this timely report available to provide you with insights into the current hydrocodone marketplace.

Download Report Details

or order complete report

To order your report or for additional details please contact:

William Kolek, President, Pain Insights, Inc. (wk@paininsights.com)
or
Bob Catuosco, Vice President, Pain Insights, Inc. (rc@paininsights.com)
or call (973) 808-1147

Order with PayPal

License Options:

Report format: PowerPoint/PDF

The Powerpoint-style report will be emailed as a PDF and is available as a Single Site License (permits only employees within the same geographical location within the organization to access it) or as a Global License (permits all employees within an organization across geographic locations to access it).

In-person or WebEx presentations available upon request.